Literature DB >> 32901436

Mannitol Augments the Effects of Systemical Stem Cell Transplantation without Increasing Cell Migration in a Stroke Animal Model.

Sang-Hoon Lee1, Ho-Young Kang1, Jong-Hoon Kim2, Dong-Hyuk Park3,4.   

Abstract

BACKGROUND: Mannitol increases blood-brain barrier permeability and can improve the efficiency of systemically administered stem cells by facilitating stem cell entry from the periphery into the injured brain. The aim of this study was to elucidate the neuroprotective effects of a combination of mannitol pretreatment and stem cell transplantation on stroke-induced neural injury.
METHODS: The experimental rats were randomly assigned to three groups 24 h after middle cerebral artery occlusion and reperfusion. One group received intravenous (IV) injections of phosphate-buffered saline (vehicle), another group received IV injections of human adipose-derived stem cells (hADSCs), and the last group received IV injections of hADSCs 10 min after IV mannitol injections. Neurobehavioral functions and infarct volume were compared. Immunohistochemistry (IHC) analyses were performed using antibodies against ionized calcium binding adapter-1 (IBA-1), rat endothelial antigen-1 (RECA-1), and bromodeoxyuridine/doublecortin (BrdU/DCX).
RESULTS: PKH-26 labeling revealed no difference in the number of stem cells that had migrated into the injured brain, and hADSC transplantation did not improve the infarct volume. However, neurobehavioral functions improved in the mannitol group. IHC showed higher numbers of RECA-1-positive cells in the peri-infarcted brain and BrdU-/DCX-colocalized cells in the subventricular zone in the mannitol group. IBA-1-positive cell number decreased in the hADSC-only and mannitol-pretreatment groups compared with the vehicle group even though there was no difference between the former two groups.
CONCLUSION: Combinatorial treatment with mannitol and hADSC transplantation may have better therapeutic potential than hADSC monotherapy for ischemic stroke.

Entities:  

Keywords:  Combination; Human adipose-derived stem cells; Ischemic stroke; Mannitol; Pretreatment

Year:  2020        PMID: 32901436      PMCID: PMC7524994          DOI: 10.1007/s13770-020-00293-1

Source DB:  PubMed          Journal:  Tissue Eng Regen Med        ISSN: 1738-2696            Impact factor:   4.169


  34 in total

Review 1.  The use of ADSCs as a treatment for chronic stroke.

Authors:  Tzu-Min Chan; Horng-Jyh Harn; Hui-Ping Lin; Shao-Chih Chiu; Po-Cheng Lin; Hsin-I Wang; Li-Ing Ho; Chih-Pin Chuu; Tzyy-Wen Chiou; An-Cheng Hsieh; Yu-Wen Chen; Wen-Yu Ho; Shinn-Zong Lin
Journal:  Cell Transplant       Date:  2014       Impact factor: 4.064

2.  Feasibility and Safety of Intra-arterial Pericyte Progenitor Cell Delivery Following Mannitol-Induced Transient Blood-Brain Barrier Opening in a Canine Model.

Authors:  Sung Won Youn; Keun-Hwa Jung; Kon Chu; Jong-Young Lee; Soon-Tae Lee; Jae-jun Bahn; Dong-Kyu Park; Jung-Suk Yu; So-Yun Kim; Manho Kim; Sang Kun Lee; Moon-Hee Han; Jae-Kyu Roh
Journal:  Cell Transplant       Date:  2014-06-13       Impact factor: 4.064

Review 3.  The global burden of stroke and need for a continuum of care.

Authors:  Bo Norrving; Brett Kissela
Journal:  Neurology       Date:  2013-01-15       Impact factor: 9.910

4.  Stem cell transplantation: the lung barrier.

Authors:  S Schrepfer; T Deuse; H Reichenspurner; M P Fischbein; R C Robbins; M P Pelletier
Journal:  Transplant Proc       Date:  2007-03       Impact factor: 1.066

5.  The combination of mannitol and temozolomide increases the effectiveness of stem cell treatment in a chronic stroke model.

Authors:  Chunggab Choi; Hye Min Kim; Jeeheun Shon; Jiae Park; Hyeong-Taek Kim; Suk Ho Kang; Seung-Hun Oh; Nam Keun Kim; Ok Joon Kim
Journal:  Cytotherapy       Date:  2018-06       Impact factor: 5.414

Review 6.  Inflammation and glial responses in ischemic brain lesions.

Authors:  G Stoll; S Jander; M Schroeter
Journal:  Prog Neurobiol       Date:  1998-10       Impact factor: 11.685

7.  Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association.

Authors:  Bruce Ovbiagele; Larry B Goldstein; Randall T Higashida; Virginia J Howard; S Claiborne Johnston; Olga A Khavjou; Daniel T Lackland; Judith H Lichtman; Stephanie Mohl; Ralph L Sacco; Jeffrey L Saver; Justin G Trogdon
Journal:  Stroke       Date:  2013-05-22       Impact factor: 7.914

8.  Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian's Disease.

Authors:  Ji Yong Lee; Hyun Soo Kim; Sung Hoon Kim; Han-Soo Kim; Byung Pil Cho
Journal:  Tissue Eng Regen Med       Date:  2020-01-22       Impact factor: 4.169

9.  Human Neural Stem Cell Induced Functional Network Stabilization After Cortical Stroke: A Longitudinal Resting-State fMRI Study in Mice.

Authors:  Anuka Minassian; Claudia Green; Michael Diedenhofen; Stefanie Vogel; Simon Hess; Maren Stoeber; Marina Dobrivojevic Radmilovic; Dirk Wiedermann; Peter Kloppenburg; Mathias Hoehn
Journal:  Front Cell Neurosci       Date:  2020-04-07       Impact factor: 5.505

Review 10.  Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.

Authors:  Valery L Feigin; Mohammad H Forouzanfar; Rita Krishnamurthi; George A Mensah; Myles Connor; Derrick A Bennett; Andrew E Moran; Ralph L Sacco; Laurie Anderson; Thomas Truelsen; Martin O'Donnell; Narayanaswamy Venketasubramanian; Suzanne Barker-Collo; Carlene M M Lawes; Wenzhi Wang; Yukito Shinohara; Emma Witt; Majid Ezzati; Mohsen Naghavi; Christopher Murray
Journal:  Lancet       Date:  2014-01-18       Impact factor: 79.321

View more
  1 in total

1.  Conditioned Medium of Human Pluripotent Stem Cell-Derived Neural Precursor Cells Exerts Neurorestorative Effects against Ischemic Stroke Model.

Authors:  Hye-Jin Hur; Ji Yong Lee; Do-Hun Kim; Myung Soo Cho; Sangsik Lee; Han-Soo Kim; Dong-Wook Kim
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.